Search results for "BONE METASTASIS"

showing 10 items of 59 documents

Bone metastasis of a breast cancer detected by 3'-deoxy-3'-18F-fluorothymidine PET/CT

2008

International audience

Adultmedicine.medical_specialtyBone NeoplasmsBreast NeoplasmsDocetaxel[SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicine030204 cardiovascular system & hematology01 natural sciencesBone and Bones[SDV.IB.MN] Life Sciences [q-bio]/Bioengineering/Nuclear medicine[ SDV.IB.MN ] Life Sciences [q-bio]/Bioengineering/Nuclear medicine03 medical and health sciences0302 clinical medicineBreast cancermedicineHumansRadiology Nuclear Medicine and imagingComputingMilieux_MISCELLANEOUSEpirubicinPET-CT010405 organic chemistrybusiness.industryBone metastasisGeneral Medicinemedicine.diseaseDideoxynucleosides3. Good health0104 chemical sciences18f fluorothymidineTreatment OutcomePositron-Emission TomographyFemaleTaxoidsRadiologybusinessTomography X-Ray Computed
researchProduct

Effects of zoledronic acid on proteinase plasma levels in patients with bone metastases.

2006

Background: The effects of the bisphosphonate derivative zoledronic acid (ZA) on the > circulating levels of matrix metalloproteinase-2 (MMP-2), matrix metallo-proteinases-9 > (MMP-9), cathepsin B (Cath B) and urokinase-type plasminogen activator (uPA) in > patients with bone metastasis (BMTS) and the possible correlation with the symptomatic > response induced by this drug in these patients were evaluated. Patients and Methods: > Proteinase levels were determined by enzyme-linked immunosorbent assay (ELISA) in the > plasma of 30 patients with painful bone metastases from breast or prostate cancer > undergoing multiple treatment with ZA (4 mg i.v., every 4 weeks). Healthy subjects > (HS) of…

Aged 80 and overMaleBone Density Conservation AgentsDiphosphonatesZoledronic > acidImidazolesProstatic NeoplasmsBone NeoplasmsBreast NeoplasmsMiddle AgedProteinaseZoledronic AcidCathepsin BMatrix > metalloproteinase-9Matrix Metalloproteinase 9Matrix metalloproteinase-2Bone metastasiBisphosphonates; Bone metastasis; Cathepsin B; Matrix metalloproteinase-2; Matrix > metalloproteinase-9; Proteinases; Urokinase-type plasminogen activator; Zoledronic > acidHumansMatrix Metalloproteinase 2BisphosphonateFemaleUrokinase-type plasminogen activatorAged
researchProduct

Receptor Activator of NF-kB (RANK) Expression in Primary Tumors Associates with Bone Metastasis Occurrence in Breast Cancer Patients

2011

Background\ud Receptor activator of NFkB (RANK), its ligand (RANKL) and the decoy receptor of RANKL (osteoprotegerin, OPG) play a pivotal role in bone remodeling by regulating osteoclasts formation and activity. RANKL stimulates migration of RANK-expressing tumor cells in vitro, conversely inhibited by OPG.\ud \ud Materials and Methods\ud We examined mRNA expression levels of RANKL/RANK/OPG in a publicly available microarray dataset of 295 primary breast cancer patients. We next analyzed RANK expression by immunohistochemistry in an independent series of 93 primary breast cancer specimens and investigated a possible association with clinicopathological parameters, bone recurrence and surviv…

Anatomy and PhysiologyMicroarraysSettore MED/06 - Oncologia MedicaCancer TreatmentLigandsMetastasisBone remodelingMetastasisBasic Cancer ResearchBreast TumorsBone and Soft Tissue SarcomasNeoplasm MetastasisMusculoskeletal SystemOligonucleotide Array Sequence AnalysisMultidisciplinaryPredictive markerReceptor Activator of Nuclear Factor-kappa BQRBone metastasisMiddle AgedImmunohistochemistryGene Expression Regulation NeoplasticOncologyRANKLMedicineFemaleResearch Articlemusculoskeletal diseasesmedicine.medical_specialtyHistologyScienceBone NeoplasmsBreast NeoplasmsBiologyBreast cancerAntibody TherapySDG 3 - Good Health and Well-beingOsteoprotegerinInternal medicinemedicineHumansRNA MessengerBoneBiologyAgedBreast cancer bone metastasis RANK-RANKLRANK LigandOsteoprotegerinComputational BiologyCancers and NeoplasmsRANK Ligandmedicine.diseaseEndocrinologyCancer researchbiology.protein
researchProduct

Focused Ultrasound Effects on Osteosarcoma Cell Lines

2019

MRI guided Focused Ultrasound (MRgFUS) has shown to be effective therapeutic modality for non-invasive clinical interventions in ablating of uterine fibroids, in bone metastasis palliative treatments, and in breast, liver, and prostate cancer ablation. MRgFUS combines high intensity focused ultrasound (HIFU) with MRI images for treatment planning and real time thermometry monitoring, thus enabling non-invasive ablation of tumor tissue. Although in the literature there are several studies on the Ultrasound (US) effects on cell in culture, there is no systematic evidence of the biological effect of Magnetic Resonance guided Focused Ultrasound Surgery (MRgFUS) treatment on osteosarcoma cells, …

Article SubjectUterine fibroidsSettore MED/06 - Oncologia MedicaCell Survivalmedicine.medical_treatmentlcsh:MedicineBone NeoplasmsThermometryBone NeoplasmGeneral Biochemistry Genetics and Molecular Biology030218 nuclear medicine & medical imaging03 medical and health sciencesProstate cancer0302 clinical medicineSettore BIO/13 - Biologia ApplicataOsteogenesisCell Line TumormedicineHumansOsteosarcomaGeneral Immunology and Microbiologymedicine.diagnostic_testbusiness.industryPhantoms ImagingOsteogenesiUltrasoundlcsh:RBone metastasisMagnetic resonance imagingGeneral Medicinemedicine.diseaseAblationMagnetic Resonance ImagingHigh-intensity focused ultrasound3. Good healthSurgery Computer-Assisted030220 oncology & carcinogenesisOsteosarcomaHigh-Intensity Focused Ultrasound AblationSettore MED/46 - Scienze Tecniche Di Medicina Di LaboratoriobusinessNuclear medicineSettore MED/36 - Diagnostica Per Immagini E RadioterapiaHumanResearch ArticleBioMed Research International
researchProduct

PHENOTYPIC PROFILING OF OSTEOTROPIC BREAST CANCER CELLS

2015

One of the preferred locations of metastases from breast cancer is the bone tissue. On the other hand, it should be recalled that mammary tumors with equal clinical diagnosis have a different course, and also different metastatic progression. Therefore, it would be helpful to have appropriate markers of osteotropism to test on the surgical cancer tissues, in order to predict the possible propensity of the breast cancer to generate bone metastases and to adequate the therapeutic plan. We previously reported1,2 on the setting-up of an in vitro model for the study of the osteotropic propensity of breast cancer cells and the influences exerted by the bone microenvironment on the cancer cells ph…

BONE METASTASIS PROTEOMICS
researchProduct

Cathepsin L in metastatic bone disease: therapeutic implications

2010

AbstractCathepsin L is a lysosomal cysteine proteinase primarily devoted to the metabolic turnover of intracellular proteins. However, accumulating evidence suggests that this endopeptidase might also be implicated in the regulation of other important biological functions, including bone resorption in normal and pathological conditions. These findings support the concept that cathepsin L, in concert with other proteolytic enzymes involved in bone remodeling processes, could contribute to facilitate bone metastasis formation. In support of this hypothesis, recent studies indicate that cathepsin L can foster this process by triggering multiple mechanisms which, in part, differ from those of t…

Bone diseaseClinical BiochemistryBone NeoplasmsBone metastasis; cancer; cathepsin K; cathepsin L; cysteine proteinases; proteinase inhibitorsBiologycathepsin KBiochemistryBone and BonesBone resorptioncathepsin LBone remodelingcysteine proteinaseCathepsin LmedicineCathepsin KAnimalsHumanscancerNeoplasm MetastasisMolecular BiologyCathepsinProteolytic enzymesproteinase inhibitorsBone metastasismedicine.diseaseBone metastasiCancer researchbiology.proteinSettore BIO/14 - Farmacologia
researchProduct

Circulating cathepsin K and cystatin C in patients with cancer related bone disease: clinical and therapeutic implications.

2007

Abstract The clinical significance of serum cathepsin K and cystatin C was assessed in patients with breast cancer (BCa) or prostate cancer (PCa) with confined disease (M0) or bone metastasis (BM). Cathepsin K and cystatin C circulating levels were determined by ELISAs in 63 cancer patients, in 35 patients with nonmalignant diseases and in 42 healthy blood donors (control group). In BCa patients, cathepsin K serum levels were significantly lower than in sex matched control group (HS; p  = 0.0008) or in patients with primary osteoporosis (OP; p  = 0.0009). On the contrary, cystatin C levels were significantly higher in BCa patients than in HS ( p  = 0.0001) or OP ( p  = 0.017). In PCa patien…

CA15-3Malemedicine.medical_specialtyCathepsin KProstatic HyperplasiaBone NeoplasmsBreast NeoplasmsEnzyme-Linked Immunosorbent Assayurologic and male genital diseasesZoledronic AcidProstate cancerInternal medicinemedicineCathepsin KBiomarkers TumorHumansCystatin CAgedPharmacologyAged 80 and overbiologyBone Density Conservation AgentsDiphosphonatesbusiness.industryBone cancerImidazolesCancerBone metastasisProstatic NeoplasmsGeneral MedicineMiddle Agedmedicine.diseaseCathepsinsCystatinsBone metastasis; cathepsin K; Cystatin CEndocrinologyZoledronic acidCystatin CROC CurveBone metastasiCase-Control Studiesbiology.proteinDisease ProgressionOsteoporosisFemaleDrug Monitoringbusinessmedicine.drugBiomedicinepharmacotherapy = Biomedecinepharmacotherapie
researchProduct

Immunogenic properties of renal cell carcinoma and the pathogenesis of osteolytic bone metastases.

2009

The immunogenic properties of renal cell carcinoma (RCC) on bone osteolysis were investigated. mRNA expression of three proinflammatory cytokines, monocyte chemotactic protein-1 (MCP-1), interleukin-6 (IL-6) and interleukin-8 (IL-8), were determined in a panel of RCC lines (CRBM 1990, ACHN and Caki-1). Moreover proinflammatory cytokine mRNA expression and protein levels of adhesion molecules, intercellular adhesion molecule-1 (ICAM-1) and E-selectin, on human umbilical vein endothelial cells (HUVEC) incubated with the conditioned media from RCC lines were evaluated. RCC express mRNA of MCP-1, IL-6 and IL-8 that may induce a proinflammatory phenotype in endothelial cells. mRNA expression of …

Cancer ResearchPathologymedicine.medical_specialtyOsteolysisVascular Cell Adhesion Molecule-1Bone NeoplasmsOsteolysisBiologyurologic and male genital diseasesModels BiologicalProinflammatory cytokineOsteoclastmedicineHumansCarcinoma Renal CellCells CulturedCell adhesion moleculeMonocyteBone metastasisEndothelial Cellsmedicine.diseaseIntercellular Adhesion Molecule-1Kidney NeoplasmsEndothelial stem cellmedicine.anatomical_structureOncologyGene Expression RegulationCulture Media ConditionedCancer researchCytokinesCytokine secretionInflammation MediatorsE-SelectinInternational journal of oncology
researchProduct

C-Kit and Its Ligand Stem Cell Factor: Potential Contribution to Prostate Cancer Bone Metastasis

2008

AbstractThe tyrosine kinase receptor c-kit and its ligand stem cell factor (SCF) have not been explored in prostate cancer (PC) bone metastasis. Herein, we found that three human PC cell lines and bone marrow stromal cells express a membrane-bound SCF isoform and release a soluble SCF. Bone marrow stromal cells revealed strong expression of c-kit, whereas PC cells showed very low levels of the receptor or did not express it all. Using an experimental model of PC bone metastasis, we found that intraosseous bone tumors formed by otherwise c-kit–negative PC3 cells strongly expressed c-kit, as demonstrated using immunohistochemical and Western blot analyses. Subcuta-neous PC3 tumors were, howev…

Cancer ResearchStromal cellbiologyBone metastasisStem cell factorlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaselcsh:RC254-282Receptor tyrosine kinaseProstate cancermedicine.anatomical_structureCell culturemedicineCancer researchbiology.proteinImmunohistochemistryBone marrowNeoplasia
researchProduct

Use of bone scintigraphy in the early diagnosis of bisphosphonate related osteonecrosis of the jaw. Case report and review of the literature

2018

The main aim of the present report is to show the potential utility of bone scintigraphy for the diagnosis of jaw osteonecrosis. We report the history of a 62-year-old woman underwent breast cancer surgery in 2010. Moreover, patient received postoperative radiotherapy and chemotherapy. Intravenous bisphosphonates were also added to the treatment strategy to reduce the risk of bone metastasis. However, a hypermetabolic focus on left hemimandible was evidenced with a bone scintigraphy during follow up. After a careful study, the diagnosis of Bisphosphonate Related Ostneonecrosis of the Jaw (BRONJ) was carried out. This case highlights that bone scintigraphy may be extremely helpful for the ea…

Chemotherapymedicine.medical_specialtyOral Medicine and Pathologymedicine.diagnostic_testbusiness.industrymedicine.medical_treatmentPostoperative radiotherapyEarly detectionBone metastasisCase Report030206 dentistryBisphosphonate:CIENCIAS MÉDICAS [UNESCO]medicine.disease03 medical and health sciences0302 clinical medicineBreast cancerBone scintigraphy030220 oncology & carcinogenesisUNESCO::CIENCIAS MÉDICASmedicineRadiologybusinessOsteonecrosis of the jawGeneral Dentistry
researchProduct